linjc16/ctgov huggingface dataset:
Thalamic Nuclei Volumes in Multiple Sclerosis

Study Overview
=================
Brief Summary
-----------------
The thalamus is composed of several nuclei interlocked in a complex anatomy. In multiple sclerosis (MS), the thalamus can be altered due to disconnection by white matter lesions and due to direct damages that could be partly mediated by CSF. Due to such pathophysiology and complex anatomy, some nuclei could be more vulnerable to multiple sclerosis than others. We will test this hypothesis by using a new algorithm to automatically segment several nuclei that we will be applied to the French national MS database

Official Title
-----------------
Differential Vulnerability of Individual Thalamic Nuclei: Toward New Biomarkers in Multiple Sclerosis

Conditions
-----------------
Multiple Sclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria : Patient older than 18 years old. With Multiple Sclerosis according to Mc Donald 2017 criteria or with clinically isolated syndrome and included with OFSEP cohort. Phenotype known (RR, SP, PP or CIS). Date of diagnosis known. With at least one MRI that includes 3D T1 and FLAIR at 1.5T or 3T. Exclusion Criteria : Stroke Other causes of dementia not caused by Multiple Sclerosis (Alzheimer's disease, Parkinsonian syndromes…)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Volume of thalamic nuclei | Volume of individual thalamic nuclei according to disease duration. | At inclusion in the cohort | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Multiple sclerosis, Thalamus, Nuclei, Atrophy
Cardiovascular Evaluation Before Renal Transplantation

Study Overview
=================
Brief Summary
-----------------
Due to rising importance of cardiovascular disease before and after renal transplantation we have changed our standard diagnostic procedure and perform stress echocardiography and myocardial scintigraphy. We would like to monitor these results and the outcome of our patients.

Detailed Description
-----------------
Chronic kidney disease is a well-known risk factor for cardiovascular disease. Patients waiting for a renal transplantation usually undergo an extensive diagnostic procedure to avoid complications after transplantation such as neoplasia or inflammation. In the past years, cardiovascular complications before and after renal transplantation have gained more attention. We therefore have changed our standard diagnostic procedure before renal transplantation and perform stress echocardiography and myocardial scintigraphy. Thus we would like to evaluate our new standard diagnostic procedure and observe the results of these diagnostic procedures as well as their impact on clinical outcome.

Official Title
-----------------
Cardiovascular Diagnostic Before Renal Transplantation: a Prospective Study to Assess Cardiovascular Morbidity Before Renal Transplantation and to Improve Standard Diagnostic Procedures.

Conditions
-----------------
Chronic Kidney Disease, Coronary Artery Disease

Intervention / Treatment
-----------------
* Other: diagnostic procedure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: endstage renal disease preparing for renal transplantation Exclusion Criteria: children (< 18 years) women who are pregnant or nursing patients who are also awaiting heart transplantation or have already a heart transplant severe mental illness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| before renal transplantation<br>Patients with CKD IV° to V° who are actually registering for a renal transplantation in our department. | Other: diagnostic procedure<br>* Cardiovascular diagnostic standard procedure before renal transplantation using stress echocardiography and stress myocardial scintigraphy.<br>* Other names: diagnostic standard procedure;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cardiovascular morbidity |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
renal transplantation, cardiovascular morbidity, evaluation before renal transplantation
The Role of Ninjurin-1 During Systemic Inflammation

Study Overview
=================
Brief Summary
-----------------
With the underlying study the investigators address the question if Ninjurin-1 (Ninj1) expression is altered in patients with systemic inflammatory response syndrome (SIRS) in comparison to healthy volunteers. The adhesion molecule Ninj1 is induced following nerve injury where it contributes to nerve generation. Besides it is described to facilitate leukocyte migration especially in the nervous system. The investigators hypothesize that Ninj1 expression is increased in SIRS patients, which will fortify its impact during inflammation and the transferability from bench to bedside.

Official Title
-----------------
Prospective Study to Analyze Ninjurin-1 and Its Soluble Part During Systemic Inflammation

Conditions
-----------------
Ninj1 Expression, SIRS

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age > 18 years cardiac surgery patients Exclusion Criteria: included in an interventional study Preoperative Infection (e.g. Endocarditis)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy<br>Healthy individuals no infection | |
| SIRS<br>SIRS patients no included in an interventional study no peroperative infection | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ninj1 expression on blood leukocytes |  | one day post surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| grade of systemic inflammation | routine inflammatory markers will be used to evaluate the grade of inflammation e.g. procalcitonin (PCT) Interleukin 6, lipopolysaccharide (LPS) binding protein (LBP). Retrospective evaluation for sepsis (bacterial infection) | one day post surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sepsis, SIRS, Ninj1, Healthy
Other Effects of Fluvastatin Are Investigated in Patients With Metabolic Syndrome

Study Overview
=================
Brief Summary
-----------------
Other effects of fluvastatin are investigated in German patients with metabolic syndrome.

Official Title
-----------------
Other Effects of Fluvastatin Are Investigated in Patients With Metabolic Syndrome

Conditions
-----------------
Metabolic Syndrome

Intervention / Treatment
-----------------
* Drug: Fluvastatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Written informed consent Male and female patients, aged between 18 and 75 years Metabolic syndrome according to National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII) Exclusion Criteria: History of heart failure HIV positive Stroke Other protocol defined inclusion and exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Fluvastatin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in circulating marker of inflammation (C-reactive protein) after 5 weeks |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in low density lipoprotein cholesterol after 5 weeks |  |  | 
| Change from baseline in non high density lipoprotein cholesterol after 5 weeks |  |  | 
| Change from baseline in total cholesterol after 5 weeks |  |  | 
| Change from baseline in high density lipoprotein cholesterol after 5 weeks |  |  | 
| Change from baseline in oxidized low density lipoprotein cholesterol after 5 weeks |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Metabolic Syndrome, fluvastatin
Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis

Study Overview
=================
Brief Summary
-----------------
Prurigo nodularis (PN) is a common dermatological disorder, manifested as scaly nodules which appear mainly on the extensor surfaces of the limbs. PN may appear secondarily to skin scratching in chronic hepatitis, liver cirrhosis, uremia, hypothyroidism etc. Nevertheless, in many cases no underlying physical disease is present. According to the literature, in fifty percent of the patients there is co-morbidity with depression, anxiety or somatoform disorders. We hypothesize that a group of these patients may benefit from antidepressant therapy.

Conditions
-----------------
Prurigo Nodularis

Intervention / Treatment
-----------------
* Drug: citalopram (cipralex)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: prurigo nodularis age: 18-70 years agreed to participate Exclusion Criteria: younger than 18 or older than 70 pregnant or lactating women chronic diseases: cancer, neurological disorders, diseases that are known to be associated with pruritus such as liver cirrhosis, uremia, etc. sensitivity to cipralotam psychosis, bi-polar disorder, substance addiction, use of antidepressant in the previous year use of systemic therapies to prurigo nodularis such as thalidomide, cyclosporine

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: citalopram (cipralex)|10-20 mg/day, for 12 weeks.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Clinical Evaluation of Air Handling in Baby fx Oxygenator With Integrated Arterial Filter Versus Baby rx Oxygenator With Non Integrated Arterial Line Filter

Study Overview
=================
Brief Summary
-----------------
The goal of the study is the evaluation of the air handling of a new type of oxygenator versus the standard model. The new type has an integrated arterial filter. The standard model has a non integrated arterial line filter. If the air handling is as effective/ better than in the standard model this can lead to reduction of cardiopulmonary bypass circuits with their initiation of systemic inflammatory response and improve cardiopulmonary bypass safety.

Official Title
-----------------
Clinical Evaluation of Air Handling in Baby fx Oxygenator With Integrated Arterial Filter Versus Baby rx Oxygenator With Non Integrated Arterial Line Filter

Conditions
-----------------
Cardiovascular Surgical Procedure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All children with body surface area between 0.25 and 0.5 m² who need cardiac surgery with cardiopulmonary bypass. Exclusion Criteria: Urgent and norwood procedures.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| oxygenator with arterial filter<br> | |
| arterial filter<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cardiovascular surgical procedure
An Observational Study on The Health Related Quality of Life in Patients With Chronic Lymphocytic Leukaemia

Study Overview
=================
Brief Summary
-----------------
This observational study will assess the health related quality of life (HQRL) profiles of patients with chronic lymphocytic leukaemia. Using health assessment questionnaires, data will be collected from patients currently receiving therapy and from those who have finished therapy and have undergone an assessment of treatment.

Official Title
-----------------
Utility Measurement Study for Patients With Chronic Lymphocytic Leukaemia

Conditions
-----------------
Lymphocytic Leukemia, Chronic

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients, >/= 18 years of age Patients with chronic lymphocytic leukaemia Patients receiving 1st line therapy Patients receiving 2nd line therapy. This will include patients who previously have responded well to 1st line therapy (relapse was >12 months after finishing the 1st line therapy) and are receiving the same therapy again Within the past three months, patients whose treatment has been stopped after 2-3 cycles of 1st or 2nd line therapy and who have not received any further therapies Patients receiving their 3rd, 4th, 5th or 6th cycle of 1st or 2nd line therapy Patients who have completed therapy, are considered stable and are between 3-12 months post therapy Eastern Cooperative Oncology Group (ECOG) performance status 0-1 Exclusion Criteria: Clinically significant disorder (other than chronic lymphocytic leukaemia and chronic lymphocytic comorbidities) or any other condition, including alcohol or drug abuse, which may interfere with study participation or affect study conclusions Mental disability or significant mental illness, legal incapacity or limited legal capacity Current high degree of comorbid burden that might affect the accuracy of the quality of life data

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cohort<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life: EuroQol Group EQ-5D questionnaire |  | 18 months | 
| Quality of life: European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire |  | 18 months | 
| Quality of life: EORTC QLQ-CLL16 (chronic lymphocytic leukaemia) questionnaire |  | 18 months |
Cutaneous Effects of Cryogen Spray Cooling

Study Overview
=================
Brief Summary
-----------------
Cryogen Spray Cooling spurt is applied to the skin surface immediately before laser exposure. As liquid cryogen rapidly evaporates, the superficial skin temperature is reduced as a result of supplying the latent heat of vaporization. Tetrafluoroethane, an environmentally compatible, non-toxic, non-flammable freon substitute, has been demonstrated in multiple studies to be a safe and effective cooling agent and is the only cryogenic compound currently approved for dermatologic use by the Food and Drug Administration.

Detailed Description
-----------------
The researcher can use laser treatment in combination with Cryogen Spray Cooling. The specific aim of this study is to characterize the clinical cutaneous effects of varying spurt durations and spurt delivery patterns that spurt durations of 100 ms or less will result in a very low incidence (less than 2%) of clinical skin effects (redness, blistering, local skin allergic reaction or skin discoloration) in any skin type. Researchers can use Cryogen Spray Cooling to protect the skin epidermis during laser therapy to decrease treatment pain, allow safe treatment of darker skin types, and safe use of high laser fluences. Cryogen Spray Cooling with Tetrafluoroethane has been incorporated into many Food and Drug Administration approved, commercially available laser devices currently used for treatment of vascular lesions, hair removal and non-ablative skin rejuvenation.

Official Title
-----------------
Cutaneous Effects of Cryogen Spray Cooling

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Other: Cutaneous Effects of Cryogen Spray Cooling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult 18 years and older Exclusion Criteria: Age <18 History of cold sensitivity Inflammatory rash on the test site

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Effects of Cryogen Spray Cooling<br>Cutaneous Effects of Cryogen Spray Cooling | Other: Cutaneous Effects of Cryogen Spray Cooling<br>* Cutaneous Effects of Cryogen Spray Cooling<br>* Other names: CSC;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Skin cooling during laser treatment | Cryogen Spray Cooling spray cooling skin during laser treatment | 1 minute | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Skin cooling during laser treatment
Ethyl Glucuronide in Urine Samples of Pregnant Women Within the HUS ja PHHYKY Area

Study Overview
=================
Brief Summary
-----------------
In order to find how many women continue using alcohol during their pregnancies the plan is to anonymously test routine urine samples collected during pregnancies for ethylglucuronide (ETG), a metabolite of ethanol that is detectable in urine up to several days after alcohol consumptions. Altogether 600 samples are taken in the prenatal care units and the prenatal care units dedicated for the alcohol and drug abusing mothers both in the Helsinki and Lahti areas. Test results are used to estimate and compare the prevalence of severe maternal drinking in the different populations.

Official Title
-----------------
Etyyliglukuronidin Esiintyminen Virtsassa äitiysneuvola- ja äitiyspoliklinikkakäyntien yhteydessä HUS:n ja PHHYKY:n Alueella

Conditions
-----------------
Fetal Alcohol Spectrum Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnant Exclusion Criteria: -
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HUCS A<br>Mothers visiting the prenatal care units within the Helsinki area. | |
| HUCS HAL<br>Mothers visiting the prenatal care units dedicated for the alcohol and drug abusing mothers within the Helsinki area. | |
| PHHYKY A<br>Mothers visiting the prenatal care units within the Lahti area. | |
| PHHYKY HALSO<br>Mothers visiting the prenatal care units dedicated for the alcohol and drug abusing mothers within the Lahti area. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| EtG | The routine urine samples from the visitors are tested for ethyl glucuronide using dip sticks with 300ng cut off. Positve finds are confirmed in a laboratory. | Day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nicotine | The positive EtG urine samples and random negative urine samples from the visitors are tested for nicotine using dip sticks. | Day 1 | 
| Cannabis | The positive EtG urine samples and random negative urine samples from the visitors are tested for cannabis using dip sticks. | Day 1 |
Dermacyd Delicata Breeze - Photo Evaluation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to prove the absence of photo irritation and photo sensitivity potential of the product Dermacyd Breeze.

Official Title
-----------------
Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd Breeze.

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Lactic acid (Dermacid)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Phototype Skin II and III Integral skin test in the region Exclusion Criteria: Lactation or gestation Use of Antiinflammatory and/or immunosuppression drugs 15 days before the selection Diseases which can cause immunity decrease, such as HIV, diabetes Use of drug photosensitizer History of sensitivity or irritation for topic products Active cutaneous disease which can change the study results History or photodermatosis active Family or personal antecedent of cutaneous photoinduced neoplasias Presence of a precursor lesion of cutaneous neoplasia, such as nevus melanocyte and keratoses actinium Intense solar exposure in the study area Use of new drugs or cosmetics during the study The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Lactic acid (Dermacid)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The photo irritation test and the photosensitivity will be measured using UVA irradiation and evaluated according International Contact Dermatitis Research Group (ICDRG) scale. The sensibility will be evaluated according to the skin type. |  | 5 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hygiene